JSSM guidelines for erectile dysfunction

International Journal of Urology

Volumn 15, Issue 7, 2008, Pages 564-576

  Kimoto, Yasusuke ^a   Nagao, Koichi ^b   Sasaki, Haruaki ^c   Marumo, Ken ^d   Takahashi, Yoshiatsu ^e   Nishi, Seiji ^f   Ishikura, Fuminobu ^g   Futamatsu, Mayumi ^h  

^a SPINAL INJURIES CENTER   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^d TOKYO DENTAL COLLEGE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f Nishi Clinic   (Japan)

^g OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^h Marriage and Sex Counseling Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATENOLOL; ATORVASTATIN; CARBAMAZEPINE; CIMETIDINE; CLOFIBRATE; ENALAPRIL; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IMIPRAMINE; LABETALOL; LOSARTAN; METHYLDOPA; NIFEDIPINE; PAROXETINE; PHENOBARBITAL; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROMETHAZINE; PROPRANOLOL; RESERPINE; SILDENAFIL; SPIRONOLACTONE; SULPIRIDE; TADALAFIL; UNINDEXED DRUG; VARDENAFIL;

BACKACHE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSENSUS; DEPRESSION; DIABETES MELLITUS; DISEASE MARKER; DISEASE SEVERITY; DRUG ALCOHOL INTERACTION; DYSLIPIDEMIA; DYSPEPSIA; ERECTILE DYSFUNCTION; EXERCISE; FLUSHING; HEADACHE; HEALTH SURVEY; HORMONE DEFICIENCY; HUMAN; HYPERTENSION; JAPAN; LABORATORY TEST; LOWER URINARY TRACT SYMPTOM; NAION; NOSE CONGESTION; OBESITY; OPTIC NERVE DISEASE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIAPISM; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PSYCHOTHERAPY; REGISTER; REVIEW; RISK FACTOR; SEXUAL INTERCOURSE; SIDE EFFECT; SMOKING; STATISTICAL ANALYSIS; VISUAL DISORDER;

ERECTILE DYSFUNCTION; HUMANS; MALE; RISK FACTORS;

EID: 47349116003     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02060.x     Document Type: Review

References (115)

1. Lue T, Basson R, Rosen R, Giuliano F, Khoury S, Montossi F (eds). Sexual Medicine: Sexual Dysfunctions in Men and Women. Health Productions, Paris, 2004 (level I).
2. Wespes E, Amar E, Hatzichristou D et al. EAU guidelines on erectile dysfunction: an update. Eur. Urol. 2006 49 : 806 15 (level I).
3. Fukui T, Yoshida M, Yamaguchi N (eds) Minds 2007 Manual for Production of Clinical Guidelines. Igakushoin, Tokyo, 2007 (in Japanese).
4. Kubin M, Wagner G, Fugl-Meyer AR. Epidemiology of erectile dysfunction. Int. J. Impot. Res. 2003 15 : 63 71 (level I).
5. Aytaç IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999 84 : 50 6 (level IVb).
6. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 1994 151 : 54 61 (level IVb).
7. Marui E. Epidemiology of erectile dysfunction and risk factors. Igaku-no-ayumi 2002 201 : 397 400 (in Japanese). (level IVb).
8. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997 49 : 822 30 (level IVb).
9. Derby CA, Araujo AB, Johannes CB, Feldman HA, McKinlay JB. Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. Int. J. Impot. Res. 2000 12 : 197 204 (level IVb).
10. Masumori N, Tsukamoto T, Kumamoto Y et al. Decline of sexual function with age in Japanese men compared with American men: Results of two community-based studies. Urology 1999 54 : 335 44 (level IVb).
11. Marumo K, Nakashima J, Murai M. Age-related prevalence of erectile dysfunction in Japan. Assessment by the International Index of Erectile Function. Int. J. Urol. 2001 8 : 53 9 (level IVb).
12. Sasayama S, Ishii N, Ishikura F et al. Men's Health Study: epidemiology of erectile dysfunction and cardiovascular disease. Circ. J. 2003 67 : 656 9 (level IVb).
13. Terai A, Ichioka K, Matsui Y, Yoshimura K. Association of lower urinary tract symptoms with erectile dysfunction in Japanese men. Urology 2004 64 : 132 6 (level IVb).
14. Seftel AD. Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J. Urol. 2003 169 : 1999 2007 (level I).
15. McVary KT, Carrier S, Wessells H, Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J. Urol. 2001 166 : 1624 32 (level I).
16. Feldman HA, Johannes CB, Derby CA et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev. Med. 2000 30 : 328 38 (level IVa).
17. Tengs TO, Osgood ND. The link between smoking and impotence: two decades of evidence. Prev. Med. 2001 32 : 447 52 (level I).
18. Rosen MP, Greenfield AJ, Walker TG et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J. Urol. 1991 145 : 759 63 (level IVb).
19. Hirshkowitz M, Arcasoy MO, Karacan I, Williams RL, Howell JW. Nocturnal penile tumescence in cigarette smokers with erectile dysfunction. Urology 1992 39 : 101 7 (level IVb).
20. Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am. J. Epidemiol. 1994 140 : 1003 8 (level IVb).
21. Guay AT, Perez JB, Heatley GJ. Cessation of smoking rapidly decreases erectile dysfunction. Endocr. Pract. 1998 4 : 23 6 (level IVb).
22. Mirone V, Imbimbo C, Bortolotti A et al. Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study. Eur. Urol. 2002 41 : 294 7 (level IVb).
23. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000 56 : 302 6 (level IVa).
24. Minowa M, Suzuki K, Wada K, Ozaki Y. Cross national study of adolescent smoking habits in 1996. 1998 (in Japanese). (level IVb).
25. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study. I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr. Med. Res. Opin. 2004 20 : 607 17 (level IVb).
26. Sun P, Swindle R. Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study. J. Urol. 2005 174 : 244 8 (level IVa).
27. Sáenz de Tejada I, Angulo J, Cellek S et al. Pathophysiology of erectile dysfunction. J. Sex. Med. 2005 2 : 26 39 (level I).
28. Weinhardt LS, Carey MP. Prevalence of erectile disorder among men with diabetes mellitus: comprehensive review, methodological critique, and suggestions for future research. J. Sex Res. 1996 33 : 205 14 (level I).
29. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002 25 : 1458 63 (level IVa).
30. Fedele D, Coscelli C, Santeusanio F et al. Erectile dysfunction in diabetic subjects in Italy. Gruppo Italiano Studio Deficit Erettile nei Diabetici. Diabetes Care 1998 21 : 1973 7 (level IVb).
31. Sasaki H, Yamasaki H, Ogawa K et al. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res. Clin. Pract. 2005 70 : 81 9 (level IVb).
32. Vinik A, Richardson D. Erectile dysfunction in diabetes. Diabetes Rev. 1998 6 : 16 33 (level I).
33. Sairam K, Kulinskaya E, Boustead GB, Hanbury DC, McNicholas TA. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int. 2001 88 : 68 71 (level IVb).
34. Gazzaruso C, Giordanetti S, De Amici E et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004 110 : 22 6 (level IVb).
35. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J. Urol. 2004 171 : 2341 5 (•• IVb).
36. Wei M, Macera CA, Davis DR, Hornung CA, Nankin HA, Blair SN. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am. J. Epidemiol. 1994 140 : 930 7 (level IVa).
37. Saltzman EA, Guay AT, Jacobson J. Improvement of erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation. J. Urol. 2004 172 : 255 8 (level V).
38. Rizvi K, Hampson JP, Harvey JN. Do lipid lowering drugs cause erectile dysfunction? A systematic review. Fam. Pract. 2002 19 : 95 8 (level I).
39. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr. Atheroscler. Rep. 2002 4 : 397 401 (level I).
40. Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ, for the Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch. Intern. Med. 2006 166 : 207 12 (level IVb).
41. Travison TG, Shabsigh R, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The natural progression and remission of erectile dysfunction: results from the Massachusetts Male Aging Study. J. Urol. 2007 177 : 241 6 (level IVa).
42. Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann. Intern. Med. 2003 139 : 161 8 (level IVa).
43. Esposito K, Giugliano F, Di Palo C et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004 291 : 2978 84 (level IVa).
44. Araujo AB, Durante R, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom. Med. 1998 60 : 458 65 (level IVa).
45. Shiri R, Koskimäki J, Tammela TLJ, Häkkinen J, Auvinen A, Hakama M. Bidirectional relationship between depression and erectile dysfunction. J. Urol. 2007 177 : 669 73 (level IVa).
46. Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am. J. Psychiatry 2001 158 : 1623 30 (level II).
47. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur. Urol. 2003 44 : 637 49 (level IVa).
48. Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br. J. Urol. 1998 82 (Suppl 1 26 33 (level V).
49. Van Moorselaar RJA, Hartung R, Emberton M et al. Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int. 2005 95 : 603 8 (level, II), 28.
50. Brookes ST, Donovan JL, Peters TJ, Abrams P, Neal DE. Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial. BMJ 2002 324 : 1059 64 (level II).
51. Finger WW, Lund M, Slagle MA. Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice. J. Fam. Pract. 1997 44 : 33 43 (level I).
52. Montorsi F, Briganti A, Salonia A et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur. Urol. 2003 44 : 360 5 (level IVb).
53. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005 294 : 2996 3002 (level IVa).
54. Kawanishi Y, Kimura K, Yamaguchi K et al. Ischemic heart disease in patients with erectile dysfunction. Jpn. J. Urol. 2000 91 : 708 14 (abstract in English). (level IVb).
55. DeBusk R, Drory Y, Goldstein I et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am. J. Cardiol. 2000 86 : 175 81 (level I).
56. Kostis JB, Jackson G, Rosen R et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). Am. J. Cardiol. 2005 96 : 313 21 (level V).
57. Rosen RC. Psychogenic erectile dysfunction: classification and management. Urol. Clin. North Am. 2001 28 : 269 78 (level I).
58. DeBusk RF. The physiologic cost of sexual activity. In : Kloner RA (ed.). Heart Disease and Erectile Dysfunction. Human Press Totowa, New Jersey, 2004 239 50 (level V).
59. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int. J. Impot. Res. 1999 11 : 319 26 (level IVb).
60. Standardisation of Terminology Sub-Committee. The Japanese version of International Index of Erectile Function (IIEF) and IIEF5. Jpn. J. Sex. Med. 1998 13 : 35 8 (in Japanese). (level VI).
61. Shirai M, Ishii N, Takanami M et al. Validation of Japanese version of International Index of Erectile Function (IIEF). Jpn. J. Sex. Med. 1999 14 : 1 28 (in Japanese). (level IVb).
62. Working Committee of Clinical Guideline for Late Onset Hypogonadism (LOH) Syndrome. Clinical guideline for Late Onset Hypogonadism (LOH) syndrome. Jpn. J. Urol. 2007 98 (Suppl 1 1 22 (in Japanese). (level V).
63. Genitourinary tract dysfunctions. In : Workers' Compensation Benefit Guidebook. 2006 209 10 (in Japanese). (level VI).
64. Iwamoto T, Yanase T, Koh E et al. Reference ranges of total serum and free testosterone in Japanese male adults. Jpn. J. Urol. 2004 95 : 751 60 (abstract in English). (level IVb).
65. Isidori AM, Giannetta E, Gianfrilli D et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin. Endocrinol. 2005 63 : 381 94 (level I).
66. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003 362 : 419 27 (level IVa).
67. Snyder PJ. Hypogonadism in elderly men- what to do until the evidence comes. N. Engl. J. Med. 2004 350 : 440 2 (level VI).
68. Petak SM, Baskin HJ, Bergman DA, Dickey RA, Nankin HR. ACCE Clinical Practice Guidelines for the evaluation and treatment of hypogonadism in adult male patients. American Association of Clinical Endocrinologists and the American College of Endocrinology - 1996. Endocr. Pract. 1996 2 : 439 53 (level I).
69. Amano T, Imao T, Takemae K et al. Profile of serum testosterone levels after application of testosterone ointment (Glowmin) and its clinical efficacy in late-onset hypogonadism patients. J. Sex. Med. (in press) (level III).
70. Rao DS, Donatucci CF. Vasculogenic impotence. Arterial and venous surgery. Urol. Clin. North Am. 2001 28 : 309 20 (level I).
71. Kawanishi Y, Kimura K, Nakanishi R, Kojima K, Numata A. Penile revascularization surgery for arteriogenic erectile dysfunction: the long-term efficacy rate calculated by survival analysis. BJU Int. 2004 94 : 361 8 (level IVb).
72. Althof SE, Rosen R, Rubio-Aurioles E et al. Psychologic and interpersonal aspects and their management. In : Porst H, Buvat J (eds). Standard Practice in Sexual Medicine. Blackwell Publishing, Malden, 2006 18 30 (level I).
73. Eardley I, Ellis P, Boolell M, Wulff M. Onset and duration of action of sildenafil for the treatment of erectile dysfunction. Br. J. Clin. Pharmacol. 2002 53 (Suppl 1 S61 5 (level IVa).
74. Carson CC, Burnett AL, Levine LA, Nehra A. The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 2002 60 (2 Suppl 2 12 27 (level II).
75. Padma-nathan H, Eardley I, Kloner RA, Laties AM, Montorsi F. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002 60 (2 Suppl 2 67 90 (level II).
76. Shirai M, Tsukamoto T, Sato Y et al. Randomized, placebo-controlled, double-blind study of oral sildenafil in Japanese men with erectile dysfunction. Nshinihon J. Urol. 2000 62 : 373 82 (abstract in English). (level II).
77. Safety Interaction with Alcohol. Viagra interview form September 2000, 4th edn. (in Japanese). (level V).
78. Hellstrom WJ, Gittelman M, Karlin G et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003 61 : 8 14 (level II).
79. Markou S, Perimenis P, Gyftopoulos K, Athanasopoulos A, Barbalias G. Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports. Int. J. Impot. Res. 2004 16 : 470 8 (level I).
80. Stief C, Porst H, Sáenz De Tejada I, Ulbrich E, Beneke M, Vardenafil Study Group. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int. J. Clin. Pract. 2004 58 : 230 9 (level II).
81. Nagao K, Ishii N, Kamidono S, Osada T, the Vardenafil (Levitra) Clinical Trial Group. Safety and efficacy of vardenafil in patients with erectile dysfunction: result of a bridging study in Japan. Int. J. Urol. 2004 11 : 515 24 (level II).
82. Interaction with Alcohol. Levitra interview form August 2007, 7th edn. (in Japanese). (level V).
83. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int. J. Impot. Res. 2002 14 (Suppl 1 S57 64 (level II).
84. Brock GB, McMahon CG, Chen KK et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J. Urol. 2002 168 : 1332 6 (level II).
85. Kloner RA, Jackson G, Hutter AM et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am. J. Cardiol. 2006 97 : 1778 84 (level I).
86. Nagao K, Kimoto Y, Marumo K et al. Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. Urology 2006 68 : 845 51 (level II).
87. Safety Interaction with Alcohol. Ciallis interview form September 2007, 1st edn. (in Japanese). (level V).
88. Dean J, Hackett GI, Gentile V et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J. Sex. Med. 2006 3 : 650 61 (level III).
89. Rubio-Aurioles E, Porst H, Eardley I, Goldstein I, Vardenafil-Sildenafil Comparator Study Group. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J. Sex. Med. 2006 3 : 1037 49 (level III).
90. Atiemo HO, Szostak MJ, Sklar GN. Salvage of sildenafil failures referred from primary care physicians. J. Urol. 2003 170 : 2356 8 (level V).
91. Barada J. Salvage of 'sildenafil (Viagra) failures' benefits of patient and retreatment with sildenafil. Int. J. Impot. Res. 2001 13 (Suppl 4 S49 50 (level V).
92. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra®) in patients with erectile dysfunction. Urology 2002 60 (2 Suppl 2 28 38 (level V).
93. Jiann BP, Yu CC, Su CC, Huang JK. Rechallenge prior sildenafil nonresponders. Int. J. Impot. Res. 2004 16 : 64 8 (level V).
94. Hatzichristou D, Moysidis K, Apostolidis A et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur. Urol. 2005 47 : 518 22 (level V).
95. Hatzimouratidis K, Moysidis K, Bekos A, Tsimtsiou Z, Ioannidis E, Hatzichristou D. Treatment strategy for 'non-responders' to tadalafil and vardenafil: a real life study. Eur. Urol. 2006 50 : 126 33 (level V).
96. Jiann BP, Yu CC, Su CC, Tsai JY. Compliance of sildenafil treatment for erectile dysfunction and factors affecting it. Int. J. Impot. Res. 2006 18 : 146 9 (level V).
97. Sato Y, Tanda H, Kato S, Onishi S, Nitta T, Koroku M. How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. Int. J. Urol. 2007 14 : 339 42 (level V).
98. Sur RL, Kane CJ. Sildenafil citrate-associated priapism. Urology 2000 55 : 950 (level V).
99. King SH, Hallock M, Strote J, Wessells H. Tadalafil-associated priapism. Urology 2005 66 : 432 (level V).
100. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J. Neuroophthalmol. 1994 14 : 38 44 (level IVa).
101. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am. J. Ophthalmol. 1997 123 : 103 7 (level IVa).
102. Newman NJ, Scherer R, Langenberg P et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am. J. Ophthalmol. 2002 134 : 317 28 (level IVa).
103. Hatzichristou D. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality? J. Sex. Med. 2005 2 : 751 8 (level V).
104. Pharmaceuticals and Medical Devices Agency. Adverse Events Monitoring. [Cited 7 Nov 2007.] Available from URL: http://www.info.pmda.go.jp/fsearch/jsp/ menu_fukusayou_base.jsp (in Japanese) (level V).
105. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J. Urol. 1996 155 : 802 15 (level I).
106. Linet OI, Ogrinc FG, for the Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N. Engl. J. Med. 1996 334 : 873 7 (level III).
107. Nagai A. ICI. Jpn. J. Sex. Med. 2006 21 : 112 13 (abstract in English). (level V).
108. Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J. Urol. 1986 135 : 142 7 (level V).
109. Montague DK, Jarow J, Broderick GA et al. American Urological Association guideline on the management of priapism. J. Urol. 2003 170 : 1318 24 (level I).
110. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J. Urol. 1997 15 : 78 82 (level I).
111. Sasaki H, Onodera Y, Kai Y et al. Clinical evaluation of vacuum constriction device Vet-Co. Jpn. J. Sex. Med. 1997 12 : 182 3 (in Japanese). (level IVb).
112. Otani T, Kai S, Narushima M. Clinical experience of treatment for impotence by vacuum constriction device. Jpn. J. Sex. Med. 1993 8 : 37 42 (in Japanese). (level V).
113. Wespes E, Wildschutz T, Roumeguere T, Schulman CC. The place of surgery for vascular impotence in the third millennium. J. Urol. 2003 170 : 1284 6 (level IVb).
114. Montague DK, Angermeier KW. Penile prosthesis implantation. Urol. Clin. North Am. 2001 28 : 355 62 (level I).
115. Marumo K, Murai M. Penile prosthesis. Nihon Rinsho 2002 60 (Suppl 298 301 (in Japanese). (level V).